AlloHSCT in paediatric ALL and AML in complete remission: improvement over time impacted by accreditation?

Abstract:

:Allogeneic hematopoietic stem cell transplantation (alloHSCT) has become a well-established treatment option for many patients suffering from malignant and non-malignant diseases. In the past decade, high-resolution HLA-typing, remission surveillance, pre-emptive immune intervention, and standardisation in supportive care measures have substantially improved transplant outcomes. This retrospective study evaluated transplant procedures in 162 paediatric patients with acute lymphoblastic leukaemia (n = 124) or acute myeloid leukaemia (n = 38) who received their first alloHSCT in our institution over an 11-year period. We observed a significant reduction in risk of non-relapse mortality (NRM) over time (HR = 0.34, 95% CI 0.12-0.98; P = 0.05), the 4-year NRM estimate decreased from 20% in 2005-2008 to 7% in 2012-2016 (P = 0.02) and an increase in survival after relapse. There was no significant difference in patients who received a graft from a sibling, haplo, or an unrelated donor with regard to their overall survival (P = 0.45), event-free survival (P = 0.61), and non-relapse mortality (P = 0.19). Our data suggest that a specific transplant infrastructure with a highly experienced team in an accredited transplant centre likely contributes to better transplant outcomes for acute leukaemia patients in complete remission regardless of donor type.

journal_name

Bone Marrow Transplant

authors

Bakhtiar S,Salzmann-Manrique E,Hutter M,Krenn T,Duerken M,Faber J,Reinhard H,Kreyenberg H,Huenecke S,Cappel C,Bremm M,Pfirrmann V,Merker M,Barnbrock A,Schöning S,Willasch AM,Rettinger E,Soerensen J,Klingebiel TE,Jar

doi

10.1038/s41409-018-0341-z

subject

Has Abstract

pub_date

2019-05-01 00:00:00

pages

737-745

issue

5

eissn

0268-3369

issn

1476-5365

pii

10.1038/s41409-018-0341-z

journal_volume

54

pub_type

临床试验,杂志文章
  • New perspectives on the biology of acute GVHD.

    abstract::The use of allogeneic hematopoietic cell transplantation (HCT) has increased as new techniques have been developed for transplantation in patients who previously would not have been considered HCT candidates. However, its efficacy continued to be limited by the development of frequent and severe acute GVHD. The comple...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2009.328

    authors: Paczesny S,Hanauer D,Sun Y,Reddy P

    更新日期:2010-01-01 00:00:00

  • Human herpesvirus 6 is an important pathogen in infectious lung disease after allogeneic bone marrow transplantation.

    abstract::Two hundred and ten bronchoalveolar lavage (BAL) samples were obtained from 50 patients 10 days before and on defined days after allogeneic bone marrow transplantation (BMT). The samples were examined for human cytomegalovirus (HCMV) and human herpesvirus-6 (HHV-6) by polymerase chain reaction (PCR). Fifteen patients ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702569

    authors: Buchbinder S,Elmaagacli AH,Schaefer UW,Roggendorf M

    更新日期:2000-09-01 00:00:00

  • Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion.

    abstract::In this study, cytogenetic and molecular analyses were employed to assess the response to therapy in 29 chronic myeloid leukemia patients undergoing high dose chemotherapy followed by autologous stem cell infusion. Of these, 11 had previously achieved hematologic remission and cytogenetic improvement after alpha-2b in...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Lo Coco F,Mandelli F,Diverio D,Alimena G,De Fabritiis P,Meloni G,Cedrone M,Frontani M,Guerrasio A,Saglio G

    更新日期:1990-10-01 00:00:00

  • Second unrelated bone marrow transplantation without additional conditioning therapy after engraftment failure.

    abstract::A 37-year-old female highly alloimmunized by multiple transfusions received a sex matched HLA-identical unrelated bone marrow transplant for hypoplastic MDS-RA with moderate myelofibrosis. Conditioning consisted of total body irradiation, cyclophosphamide and ATG, GVHD prophylaxis consisted of CsA, MTX and prednisolon...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701079

    authors: Wolff D,Becker C,Kubel M,Pönisch W,Edelmann J,Friedrich T,Helbig W

    更新日期:1998-02-01 00:00:00

  • Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: a new prospect of exploiting extended family search.

    abstract::The best donors for hematopoietic SCT (HSCT) are fully-matched siblings. In patients without fully-matched siblings, HLA registries or cord blood banks are alternative strategies with some restrictions. Owing to the high rate of consanguineous marriage in our country, between 2006 and 2013, extended family searches we...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.307

    authors: Hamidieh AA,Dehaghi MO,Paragomi P,Navaei S,Jalali A,Eslami GG,Behfar M,Ghavamzadeh A

    更新日期:2015-04-01 00:00:00

  • Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.

    abstract::Infectious complications were retrospectively analyzed in 129 transplants, performed in 90 patients, to identify characteristics that qualify breast cancer patients for outpatient-based PBSCT. Thirty-one cases (24%) did not develop fever. Of the remaining 98 cases, 84.7% developed fever during severe neutropenia. On u...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703246

    authors: Morabito F,Irrera G,Oliva E,Console G,Martino M,Pucci G,Messina G,Barbaro P,Palazzo S,Iacopino P

    更新日期:2001-11-01 00:00:00

  • HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome.

    abstract::Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS). However, many patients cannot find an HLA-matched donor. We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized PBSCs without in vitro...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2009.351

    authors: Chen Y,Liu K,Xu L,Chen H,Liu D,Zhang X,Shi H,Han W,Wang Y,Zhao T,Wang J,Wang J,Huang X

    更新日期:2010-08-01 00:00:00

  • Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources.

    abstract::Over the last 15 years, we have performed a total of 30 haematopoietic stem cell transplants on 27 children suffering from Hurler's syndrome. These children were of median age 11 months at the time of diagnosis and 25 months at the time of transplantation. The phenotype was severe in 21 cases (78%). The donor was fami...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704105

    authors: Souillet G,Guffon N,Maire I,Pujol M,Taylor P,Sevin F,Bleyzac N,Mulier C,Durin A,Kebaili K,Galambrun C,Bertrand Y,Froissart R,Dorche C,Gebuhrer L,Garin C,Berard J,Guibaud P

    更新日期:2003-06-01 00:00:00

  • Value of cytomegalovirus detection by PCR in bronchoalveolar lavage routinely performed in asymptomatic bone marrow recipients.

    abstract::In order to compare PCR with rapid virus culture for the early detection of CMV in bronchoalveolar lavage (BAL) after bone marrow transplantation, 26 asymptomatic patients were routinely evaluated for the presence of CMV on day 35 using these two techniques. Concurrent blood samples were also analyzed in all cases. CM...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700941

    authors: Fajac A,Stéphan F,Ibrahim A,Gautier E,Bernaudin JF,Pico JL

    更新日期:1997-10-01 00:00:00

  • Graft-versus-host disease in children receiving HLA-identical allogeneic bone marrow transplants with a low adjusted T lymphocyte dose.

    abstract::Fourteen children with high risk leukaemia received allogeneic bone marrow transplants from HLA-identical MLC-compatible sibling donors. All bone marrows were T cell depleted and a T cell addback was prepared from the donor's peripheral blood so that the mean total number of CD3+ cells given was 2.6 (1.0-4.1) x 10(5)/...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Potter MN,Pamphilon DH,Cornish JM,Oakhill A

    更新日期:1991-11-01 00:00:00

  • Cerebral toxoplasmosis - a late complication of allogeneic haematopoietic stem cell transplantation.

    abstract::Toxoplasma gondii infection reactivation predominantly occurs among patients after allogeneic haematopoietic stem cell transplantation. Mostly, reactivation occurs during first 3 months after transplant, especially when risk factors are present. We report a case of late cerebral toxoplasmosis reactivation, which was p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702075

    authors: Zver S,Cernelc P,Mlakar U,Pretnar J

    更新日期:1999-12-01 00:00:00

  • Hematopoietic stem cell transplantation (HSCT) for Langerhans cell histiocytosis (LCH) in Japan.

    abstract::There exists limited information about the usefulness of hemopoietic stem cell transplantation (HSCT) for the treatment of patients with refractory Langerhans cell histiocytosis (LCH). We report here four Japanese pediatric patients with multisystem LCH disease who underwent HSCT between 1994 and 1997. Two of the four...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702001

    authors: Kinugawa N,Imashuku S,Hirota Y,Yamada K,Yamamoto A,Akazai A,Oda M,Miura N,Kakuta H,Sato T,Endo M,Takano T

    更新日期:1999-10-01 00:00:00

  • Clonal imbalances of serum immunoglobulins after allogeneic bone marrow transplantation: an analysis by high-resolution two-dimensional gel electrophoresis.

    abstract::The clonality pattern of immunoglobulins (Igs) produced after allogeneic bone marrow transplantation (BMT) was studied by high-resolution two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) of serum samples and purified Igs. With this technique, the light (L) chain of a monoclonal Ig usually appears as a sing...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Tissot JD,Helg C,Chapuis B,Zubler RH,Jeannet M,Hochstrasser DF,Hohlfeld P,Schneider P

    更新日期:1992-10-01 00:00:00

  • Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation.

    abstract::To identify a correlation between metaphase cytogenetics and relapse after reduced intensity conditioning (RIC) allotransplant for patients with multiple myeloma, data on 60 patients (median age 52) who received grafts from a sibling (n = 49) or unrelated donor (n = 11) were analyzed. Fifty-three patients (88%) showed...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705267

    authors: Lee CK,Zangari M,Fassas A,Thertulien R,Talamo G,Badros A,Cottler-Fox M,van Rhee F,Barlogie B,Tricot G

    更新日期:2006-03-01 00:00:00

  • Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR.

    abstract::Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with intermediate-risk AML, who...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.84

    authors: Imahashi N,Suzuki R,Fukuda T,Kakihana K,Kanamori H,Eto T,Mori T,Kobayashi N,Iwato K,Sakura T,Ikegame K,Kurokawa M,Kondo T,Iida H,Sakamaki H,Tanaka J,Kawa K,Morishima Y,Atsuta Y,Miyamura K

    更新日期:2013-01-01 00:00:00

  • Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.

    abstract::Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds the Flt3 (CD135) receptor expressed on hematopoietic stem cells (HSCs), early progenitor cells, immature thymocytes and steady-state dendritic cells (DCs) and induces their proliferation, differentiation, development and mobilization in the bone marrow, peripher...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2015.74

    authors: Anandasabapathy N,Breton G,Hurley A,Caskey M,Trumpfheller C,Sarma P,Pring J,Pack M,Buckley N,Matei I,Lyden D,Green J,Hawthorne T,Marsh HC,Yellin M,Davis T,Keler T,Schlesinger SJ

    更新日期:2015-07-01 00:00:00

  • Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion.

    abstract::We retrospectively compared the incidence of acute graft-versus-host disease (GVHD) before and after September 1999, when we changed the mode of cyclosporine A (CsA) administration from twice-daily infusions (TD) (n=58) to continuous infusion (CIF) (n=71). The incidence of grade II-IV acute GVHD in the CIF group (56%)...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704374

    authors: Ogawa N,Kanda Y,Matsubara M,Asano Y,Nakagawa M,Sakata-Yanagimoto M,Kandabashi K,Izutsu K,Imai Y,Hangaishi A,Kurokawa M,Tsujino S,Ogawa S,Aoki K,Chiba S,Motokura T,Hirai H

    更新日期:2004-03-01 00:00:00

  • Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft?

    abstract::Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence after auto-HSCT is poor. Some highly selected patients can benefit from second transplants. One-third with late ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2009.214

    authors: Freytes CO,Lazarus HM

    更新日期:2009-11-01 00:00:00

  • Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience.

    abstract::Between May 1994 and May 2000, we autotransplanted 48 consecutive patients, 21 females and 27 males aged over 60 years (range: 60-78, median: 63). Sixteen patients had multiple myeloma (MM), 14 high-grade non-Hodgkin's lymphoma (HGNHL), six low-grade non-Hodgkin's lymphoma (LGNHL), nine acute myeloid leukemia (AML), o...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703034

    authors: Olivieri A,Capelli D,Montanari M,Brunori M,Massidda D,Poloni A,Lucesole M,Centurioni R,Candela M,Masia MC,Tonnini C,Leoni P

    更新日期:2001-06-01 00:00:00

  • High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.

    abstract::This retrospective study from the Italian Association of Pediatric Hematology Oncology-Bone Marrow Transplant Group (AIEOP-TMO) reports the results of consolidation with high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with acute myeloid leukemia (AML) in first complet...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/sj.bmt.1703122

    authors: Cesaro S,Meloni G,Messina C,Pillon M,Proglia A,Lanino E,Caniggia M,Bagnulo S,Pession A,Locatelli F,Italian Pediatric Group for Bone Marrow Transplantation.

    更新日期:2001-07-01 00:00:00

  • Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response.

    abstract::Nine patients with advanced Hodgkin's lymphoma (HL) who had undergone allogeneic stem cell transplantation (allo-SCT) received donor leukocyte infusions (DLIs) for treatment of persistent or progressive disease (PD). A total of 15 DLIs were performed, with four patients receiving more than one DLI. In four patients, p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704621

    authors: Anderlini P,Acholonu SA,Okoroji GJ,Andersson BS,Couriel DR,De Lima MJ,Donato ML,Khouri IF,Giralt SA,Ueno NT,Champlin RE

    更新日期:2004-09-01 00:00:00

  • Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.

    abstract::High relapse rates during the first year after autologous stem cell transplantation (ASCT) for multiple myeloma or non-Hodgkin lymphoma are due to the failure of high-dose chemotherapy to eradicate minimal residual disease. Post-ASCT immunorecovery studies have shown that quantities of natural killer (NK) cells return...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703203

    authors: Porrata LF,Inwards DJ,Lacy MQ,Markovic SN

    更新日期:2001-10-01 00:00:00

  • Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation.

    abstract::The development of immune-mediated hemolytic anemia is a well-recognized complication after allogeneic bone marrow transplantation (BMT). The majority of reported cases, however, have been alloimmune in origin due to ABO or minor red blood cell antigen incompatibilities between the donor and recipient. In this study, ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Drobyski WR,Potluri J,Sauer D,Gottschall JL

    更新日期:1996-06-01 00:00:00

  • High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases.

    abstract::Germ cell cancer (GCC) is curable in metastatic stages. The International Germ Cell Cancer Collaborative Group (IGCCCG) reports a poor prognosis subgroup with a 5-year survival of 48%. High-dose chemotherapy with PBSC transplantation (HD-PBSCT) in these patients showed promising results in phase II, but failed to show...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/bmt.2012.14

    authors: Mohr M,Hartig I,Kessler T,Hamisch C,Kliesch S,Krug U,Spieker T,Semik M,Wiebe K,Pühse G,Hertle L,Liersch R,Müller-Tidow C,Mesters RM,Berdel WE

    更新日期:2012-10-01 00:00:00

  • Return of immunohematopoietic impairment a long time after murine syngeneic bone marrow transplantation.

    abstract::We have tested the immunologic status and hematologic parameters of mice 2 months (short-term survivors) or 18 months (long-term survivors) after lethal total body irradiation and syngeneic bone marrow transplantation (SBMT), and of normal mice of corresponding age. Long-term SBMT survivors showed significantly lowere...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Skórski T,Kawalec M,Ratajczak M,Szczylik C,Kawiak J

    更新日期:1990-11-01 00:00:00

  • Treatment of gonadal damage in recipients of allogeneic or autologous transplantation for haematological malignancies.

    abstract::Management of iatrogenic gonadal reproductive failure and sexual morbidity assumes a priority, especially in young recipients of high-dose chemotherapy and stem cell transplantation (SCT). Hormone replacement treatment (HRT) is beneficial for correction of sexual symptoms and osteoporosis in both sexes, especially in ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1703721

    authors: Chatterjee R,Kottaridis PD

    更新日期:2002-11-01 00:00:00

  • Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.

    abstract::We performed a retrospective analysis of the incidence, risk factors, and clinical outcome of hepatic veno-occlusive disease (VOD) in 50 children prepared for bone marrow transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg). The overall incidence of VOD was 28% (14/50). The incidence of VOD among ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Ozkaynak MF,Weinberg K,Kohn D,Sender L,Parkman R,Lenarsky C

    更新日期:1991-06-01 00:00:00

  • Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation.

    abstract::Although neurocognitive impairment has been established as a major issue among cancer survivors, the real-world consequences of this impairment are unclear. This study investigated the relationship between neurocognitive functioning and medication management ability over time among 58 patients treated with allogeneic ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2016.2

    authors: Mayo S,Messner HA,Rourke SB,Howell D,Victor JC,Kuruvilla J,Lipton JH,Gupta V,Kim DD,Piescic C,Breen D,Lambie A,Loach D,Michelis FV,Alam N,Uhm J,McGillis L,Metcalfe K

    更新日期:2016-06-01 00:00:00

  • Impact of pretransplant donor-specific anti-HLA antibodies on cord blood transplantation on behalf of the Transplant Complications Working Group of Japan Society for Hematopoietic Cell Transplantation.

    abstract::Graft failure (GF) remains a major complication of cord blood transplantation (CBT). Although the presence of pretransplant, donor-specific anti-HLA antibodies (DSA) was reported to be associated with an increased risk of GF after CBT, data are still limited. Thus, we conducted a retrospective analysis of recipients o...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0712-0

    authors: Fuji S,Oshima K,Ohashi K,Sawa M,Saito T,Eto T,Tanaka M,Onizuka M,Nakamae H,Shiratori S,Ozawa Y,Hidaka M,Nagamura-Inoue T,Tanaka H,Fukuda T,Ichinohe T,Atsuta Y,Ogata M

    更新日期:2020-04-01 00:00:00

  • Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs.

    abstract::Recombinant human (rHu) G-CSF has been widely used to treat neutropenia and mobilize PBPCs for their autologous and allogeneic transplantation. It shortens neutropenia and thus reduces the frequency of neutropenic fever. We compared the efficiency of glycosylated rHu and non-glycosylated Hu G-CSF in mobilizing hematop...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.150

    authors: Ria R,Gasparre T,Mangialardi G,Bruno A,Iodice G,Vacca A,Dammacco F

    更新日期:2010-02-01 00:00:00